CDK4/6 inhibitors enhance oxaliplatin efficacy in colorectal cancer with RB-dependent and tumor-selective activity in intestinal model
Alana S O Souza, Julia S. M. Conceição, Letícia Silva Ferraz…·Helena L. Borges
This study shows CDK4/6 inhibitors synergize with oxaliplatin in colorectal cancer, with RB-dependent tumor-selective activity and preserved efficacy at low inhibitor doses.